Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy | Zendy

Simone Krebs | Zendy; Joseph A. O’Donoghue | Zendy; Evan Biegel | Zendy; Bradley J. Beattie | Zendy; Diane ReidyLagunes | Zendy; Serge K. Lyashchenko | Zendy; Jason S. Lewis | Zendy; Lisa Bodei | Zendy; Wolfgang Weber | Zendy; Neeta PanditTaskar | Zendy

Open Access

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

Author(s) -

Simone Krebs,

Joseph A. O’Donoghue,

Evan Biegel,

Bradley J. Beattie,

Diane ReidyLagunes,

Serge K. Lyashchenko,

Jason S. Lewis,

Lisa Bodei,

Wolfgang Weber,

Neeta PanditTaskar

Publication year - 2020

Publication title -

european journal of nuclear medicine and molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.313

H-Index - 163

eISSN - 1619-7089

pISSN - 1619-7070

DOI - 10.1007/s00259-020-04832-9

Subject(s) - radionuclide therapy , dota , medicine , nuclear medicine , neuroendocrine tumors , pet ct , lesion , positron emission tomography , radiology , pathology , in vivo , microbiology and biotechnology , biology

Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68 Ga-DOTA-JR11 and 177 Lu-satoreotide tetraxetan ( 177 Lu-DOTA-JR11) in patients with NETs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research